• Recognizing the burden

    Non-communicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally.

    Each year, 17 million people die from a NCD before age 70; 86% of these premature deaths occur in low- and middle-income countries.

    (WHO, 2022)

  • Estimating the impact

    Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million including kidney disease deaths caused by diabetes).

    (WHO, 2022)

  • Prevention and control

    Prevention, diagnosis and management of cardio vascular diseases and diabetes is achieved through the monitoring of various laboratory parameters, such as lipids for atherosclerosis, blood glucose for diabetes, serum creatinine for chronic kidney disease, and liver enzymes for liver disease.

    (Vetter et al. BMC Cardiovasc Disord (2021) 21:486)

  • Diabetes burden of disease

    Global Burden of Disease (GBD) study assesses mortality and disability from hundreds of diseases, injuries, and risk factors around the world.

    The Global Burden of Disease is a critical resource for informed policymaking.

  • Noncommunicable Diseases Data Portal

    The noncommunicable diseases data portal aims to raise awareness on progress in tackling NCDs and their risk factors and strengthen accountability for action by countries. It displays data to highlight current status of NCD mortality, morbidity and risk factor exposures, and track global and national progress against key targets, identify common challenges, and signpost useful resources

    Users can explore the data below by country, accessing detailed information on noncommunicable diseases and their key risk factors.

  • HbA1c testing in primary care improves outcomes

    In this review article, the authors describe HbA1c testing as a marker of glycemic control and the standard for diabetes risk assessment. They highlight that many people living with uncontrolled diabetes, have increasing the risk of microvascular complications. They explain that a lack of HbA1c monitoring presents a significant barrier and that improving ease of testing could improve glycemic control.

Use Cases

A study showed that using HbA1c devices in primary care settings is a cost-effective alternative for monitoring glycated hemoglobin A1c as a marker of blood glucose control in people living with type 2 diabetes in Brazil.

Read more

Browse diagnostics

FAQs

Why is it necessary to monitor blood glucose level in diabetes management?

Many people living with uncontrolled diabetes have increased risk of microvascular complications and death.

What is the role of Hb1Ac testing in diabetes management?

Hemoglobin A1c testing provides a marker of glycemic control and is the standard for diabetes risk assessment. According to the Centers for Disease Control (CDC), only 67.3-71.4% of people living with diabetes between 2011 and 2016 had at least two A1c levels tested per year. Moreover, 27.8% had uncontrolled diabetes with an A1c of ≥8.0%, increasing the risk of microvascular complications. Lack of monitoring presents a significant barrier, and improving ease of testing could improve glycemic control.

What is the difference between BGM and CGM?

BGM (blood glycose monitoring) is a static measurement that provides an accurate instant glucose level but does not provide information about changes in glucose levels over time. In contrast, CGM (continuous glucose monitoring) is a dynamic measurement that provides information about both the current value and changes in glucose levels over time.

Disclaimer: The Learn Resources section is a compilation of information on a given topic that is drawn from credible sources; however, this does not claim to be an exhaustive document on the subject. It is not intended to be prescriptive, nor does it represent the opinion of FIND or its partners.